HU14.18-IL2
HU14.18-IL2 Uses, Dosage, Side Effects, Food Interaction and all others data.
HU14.18-IL2 is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
| Trade Name | HU14.18-IL2 |
| Generic | Lorukafusp alfa |
| Lorukafusp alfa Other Names | EMD 273063, HU14.18-IL2, Lorukafusp alfa |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here HU14.18-IL2
